ARVD9

Arrhythmogenic right ventricular dysplasia Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Arrhythmogenic right ventricular dysplasia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
X - Ray
ECG
Cardiac MRI
Echocardiogram
Other Imaging Findings
Endomyocardial biopsy
Atuopsy
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
ARVD9 On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of ARVD9 All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
National Guidelines Clearinghouse
NICE Guidance
FDA on ARVD9
CDC on ARVD9
ARVD9 in the news
Blogs onARVD9
Directions to Hospitals Treating Arrhythmogenic right ventricular dysplasia
Risk calculators and risk factors for ARVD9

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Arrhythmogenic right ventricular dysplasia type 9; arrhythmogenic right ventricular cardiomyopathy 9; ARVC9

Overview

Arrhythmogenic right ventricular dysplasia is a type of nonischemic cardiomyopathy that involves primarily the right ventricle. It is characterized by hypokinetic areas involving the free wall of the right ventricle, with fibrofatty replacement of the right ventricular myocardium, with associated arrhythmias originating in the right ventricle.

Pathophysiology

The pathogenesis of ARVD involves apoptosis with fatty and fibro-fatty infiltration of the right ventricular free wall leading to heart failure and ventricular arrhythmias.

Genetics

This variant (609040) is associated with a mutation in the PKP2 gene (602861) on chromosome 12p11.